20-02-2025
Celltrion, CJ Bioscience strengthen European presence at ECCO'25
Celltrion and CJ Bioscience are set to showcase their global competitiveness through research findings at the 2025 European Crohn's and Colitis Organization congress, one of the world's most prestigious inflammatory bowel disease research gatherings, which kicked off Thursday in Berlin.
As Europe's largest IBD conference, ECCO draws over 8,000 medical professionals annually from around the world, including North America and Asia. The four-day event serves as a key platform for discussions on cutting-edge clinical research and emerging treatment approaches. Celebrating its 20th anniversary, this year's conference is themed 'Sustainability in IBD and Beyond.'
As the only Korean company participating as an official sponsor, Celltrion is aiming to make a strong impact with a dedicated booth showcasing scientific programs.
The company is set to present research findings on the treatment outcomes of moderate to severe ulcerative colitis patients using Remsima SC. Additionally, Celltrion will unveil three poster presentations, covering clinical recovery time after dose escalation in patients with loss of response, the efficacy of maintenance therapy based on disease location in Crohn's disease patients, and the impact of immunogenicity in two-year clinical data from Crohn's disease patients.
'The newly presented research data is expected to further strengthen the preference for Remsima SC,' a Celltrion official said. 'It will not only reinforce our position in Europe but also enhance trust in our products in key regions such as the US, Asia and Latin America, where we are preparing for prescription expansion and new product launches.'
According to market research firm IQVIA, Remsima SC has captured 25 percent of the market share across five major European countries -- Germany, Spain, the UK, Italy and France, as of the third quarter of 2024. When combined with the intravenous formulation of Remsima, the overall market share across these EU nations reaches 79 percent.
Meanwhile, marking its first-ever participation at ECCO, CJ Bioscience is unveiling its latest research findings on CJRB-201, a promising microbiome-based drug candidate developed through Ez-Mx, an AI-powered drug discovery platform. The company will present new data on the drug's anti-inflammatory effects and mechanism of action, backed by immune analysis and animal studies.
"While antibody-based therapies are often challenging to administer and lack sustained safety, CJRB-201 is designed to offer superior safety and enhanced usability for prolonged treatment," a CJ Bioscience official said, adding that the company is preparing to initiate clinical development next year.
